Myxofibrosarcoma of the heart: case series
https://doi.org/10.35336/VA-2022-1-08
Abstract
Intraluminal formations of the heart are a heterogeneous group: from blood clots to malignant neoplasms. The nosology of these formations can only be determined by morphological research. Myxofibrosarcoma of the heart is a rare malignant tumor. According to modern concepts, myxofibrosarcoma belongs to the group of intimal sarcomas, subgroup of undifferentiated pleomorphic sarcomas. We describe two cases of myxofibrosarcoma of the heart: in one subject against the background of inflammatory myofibroblastic heart tumor; in another subject - with a history of breast cancer and diffuse large B-cell lymphoma. An attempt was made to identify similar mutations in patients with these tumors according to the literature.
About the Authors
I. A. Makarov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Saint-Petersburg, 2 Akkuratova str.
L. B. Mitrofanova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Saint-Petersburg, 2 Akkuratova str.
I. B. Antonova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Saint-Petersburg, 2 Akkuratova str.
I. A. Danilova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Saint-Petersburg, 2 Akkuratova str.
A. O. Khazratov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Saint-Petersburg, 2 Akkuratova str.
V. S. Sidorin
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Saint-Petersburg, 2 Akkuratova str.
References
1. Rahouma M, Arisha MJ, Elmously A, et al. Cardiac tumors prevalence and mortality: A systematic review and meta-analysis. Int J Surg. 2020;76: 178-189. https://doi.org/10.1016/j.ijsu.2020.02.039.
2. Narla LD, Newman B, Spottswood SS, et al. Inflammatory pseudotumor. Radiographics. 2003;23(3): 719-29. https://doi.org/10.1148/rg.233025073.
3. Maier HC, Sommers SC. Recurrent and metastatic pulmonary fibrous histiocytoma/plasma cell granuloma in a child. Cancer. 1987;60(5): 1073-6. https://doi.org/10.1002/1097-0142(19870901)60:53.0.co;2-o.
4. Kovach, SJ, Fischer, AC, Katzman, PJ et al. Inflammatory myofibroblastic tumors. J. Surg. Oncol. 2006;94: 385- 391. https://doi.org/10.1002/jso.20516.
5. Burke A, Fabio R, Joseph J, et al. Tumors of the Heart and Great Vessels. 2015;302-312
6. Suleymanova AM, Kachanov DYu, Imyanitov EN, et al. Inflammatory myofibroblastic tumors in children: literature review. Russian Journal of Pediatric Hematology аnd Oncology. 2020;7(2): 64-77 (In Russ).
7. Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 fusions and rare novel RET gene rearrangement. Am J Surg Pathol. 2015;39(7): 957-67. https://doi.org/10.1097/PAS.0000000000000404.
8. Wolska-Washer A, Smolewski P, Robak T. Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. Expert Opinion on Pharmacotherapy, (2021): 1-13.
9. Amos A, Fimbres А, Marcinak J, et al. Inflammatory pseudotumor of the heart caused by Listeria monocytogenes infection, Journal of Infection, 2009; 58(2): 161- 163. https://doi.org/10.1016/j.jinf.2008.12.007.
10. Rose AG, McCormick S, Cooper K, et al. Inflammatory pseudotumor (plasma cell granuloma) of the heart. Report of two cases and literature review. Arch Pathol Lab Med. 1996;120(6): 549-54.
11. Burke A, Li L, Kling E, et al. Cardiac inflammatory myofibroblastic tumor: a “benign” neoplasm that may result in syncope, myocardial infarction, and sudden death. Am J Surg Pathol. 2007;31(7): 1115-22. https://doi.org/10.1097/PAS.0b013e31802d68ff.
12. Ferbend P, Abramson LP, Backer CL, et al. Cardiac plasma cell granulomas: response to oral steroid treatment. Pediatr Cardiol. 2004;25(4): 406-10. https://doi.org/10.1007/s00246-003-0269-x.
13. Hartyánszky IL, Kádár K, Hubay M. Rapid recurrence of an inflammatory myofibroblastic tumor in the right ventricular outflow tract. Cardiol Young. 2000;10(3): 271-4. https://doi.org/10.1017/s1047951100009239.
14. Karazanishvili L, Limonjiani E. Can Primary Cardiac Myxofibrosarcoma Grow Quickly from Zero to a Size Leading to Left-Sided Heart Failure within 9 Months? Case reports in surgery. 2020: 4241204. https://doi.org/10.1155/2020/4241204.
15. Takahashi Y, Kohashi K, Yamada Y, et al. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas. Hum Pathol. 2014;45(5): 984-93. https://doi.org/10.1016/j.humpath.2013.12.012.
16. Lee JC, Li CF, Fang FM, et al. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 2010;23(10): 1379-92. https://doi.org/10.1038/modpathol.2010.128.
17. Sun D, Wu Y, Liu Y. et al. Primary cardiac myxofibrosarcoma: case report, literature review and pooled analysis. BMC Cancer. 2018;18: 512. https://doi.org/10.1186/s12885-018-4434-2
18. Badaloni F, Pozzati E, Marucci G, et al. Primary Cardiac High-grade Myxofibrosarcoma Presenting with Multiple Brain Metastases. A Case Report. Cureus. 2017;9(11): e1866. https://doi.org/10.7759/cureus.1866.
19. Zhang PJ, Brooks JS, Goldblum JR, et al. Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol. 2008;39(9): 1385-95. https://doi.org/10.1016/j.humpath.2008.01.019.
20. Yan M, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40(6): 770-80. https://doi.org/10.1016/j.ctrv.2014.02.008.
21. Yan S, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol. 2015;10: 62. https://doi.org/10.1186/s13000-015-0296-y.
22. Cui W, Zheng S, Liu Z, et al. PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro. Onco Targets Ther. 2017;10: 2239- 2247. https://doi.org/10.2147/OTT.S129970.
23. Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019;28(11): 977- 988. https://doi.org/10.1080/13543784.2019.1676726.
Review
For citations:
Makarov I.A., Mitrofanova L.B., Antonova I.B., Danilova I.A., Khazratov A.O., Sidorin V.S. Myxofibrosarcoma of the heart: case series. Journal of Arrhythmology. 2022;29(1):50-57. https://doi.org/10.35336/VA-2022-1-08
Views:
686
Email this article 